Does Bedaquiline Fumarate Interact with Cyp3a Inhibitors Moderate And Strong?
CDI records a contraindicated classification for Bedaquiline Fumarate and Cyp3a Inhibitors Moderate And Strong. The stored summary is: Coadministration may decrease systemic exposure of bedaquiline. Avoid use of strong and moderate CYP3A4 inducers with SIRTURO. The mechanism involves cyp3a4 enzyme induction decreases bedaquiline systemic exposure. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Contraindicated
- Management
- Do not take together
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
CYP3A4 enzyme induction decreases bedaquiline systemic exposure
What To Tell Your Doctor or Pharmacist
If you are taking Bedaquiline Fumarate and your doctor is considering prescribing Cyp3a Inhibitors Moderate And Strong (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask about alternative medications that do not interact with your current regimen
- Ask how frequently you should be monitored while these are co-prescribed
- Never stop or change either medication without first consulting your healthcare provider